Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines

Typewriter Therapeutics, Inc., a biotechnology company focused on developing innovative genetic medicines, has successfully raised $56 million in Series A financing. The funding round, which was announced on September 2, 2026, was led by AN Venture Partners and RA Capital Management, with additional participation from investors including ANRI, Gemseki, and SBI US Gateway Fund. This financing marks Typewriter's emergence from stealth mode and positions the company to advance its proprietary technology aimed at creating safer, durable, and re-dosable genetic therapies.

Founded in February 2022, Typewriter Therapeutics leverages its unique Target-Primed Reverse Transcription (TPRT) technology platform, which utilizes a non-viral method to insert whole genes into the genome. This approach employs lipid nanoparticle (LNP)-delivered RNA to facilitate gene insertion, thereby reducing the risks associated with viral delivery methods. The company aims to address significant medical needs in areas such as cancer, autoimmune diseases, and severe genetic disorders. Typewriter's initial focus will be on developing in vivo CAR T therapies and treatments for genetic liver diseases, with plans for non-human primate studies slated for late 2026.

The leadership team at Typewriter Therapeutics includes Matthew Stanton, PhD, who has been appointed as CEO, and Leanne Peiser, DPhil, as Chief Scientific Officer. Both executives bring extensive experience in the biotechnology and pharmaceutical sectors, with Stanton previously holding key roles at Raven and Moderna Therapeutics, while Peiser has a strong background in immunology and cellular therapy from her tenure at Bristol Myers Squibb. Additionally, the company has attracted notable figures to its board, including former Pfizer Chief Scientific Officer Mikael Dolsten, MD, PhD, who will provide strategic guidance as an independent director.

The biotechnology sector is witnessing a surge in interest and investment, particularly in the realm of genetic therapies. The successful fundraising by Typewriter Therapeutics underscores the growing confidence in innovative approaches to gene therapy, especially those that prioritize safety and durability. As the industry continues to evolve, companies that can demonstrate a clear value proposition and a strong technological foundation are likely to attract significant attention from investors and stakeholders alike.

The implications of this funding round extend beyond Typewriter Therapeutics, reflecting broader trends in the biotechnology landscape. As advancements in genetic medicine gain traction, the potential for transformative therapies to address complex diseases becomes increasingly viable. This financing not only supports Typewriter's ambitious goals but also signals a robust appetite for innovation within the sector, paving the way for future developments that could reshape treatment paradigms in oncology and beyond.